Daily Newsletter

01 December 2023

Daily Newsletter

01 December 2023

Nevro acquires medical technology company Vyrsa

Established in 2021, Vyrsa offers sacroiliac (SI) joint fusion devices approved by the US Food and Drug Administration (FDA).

RanjithKumar Dharma

Nevro has acquired medical technology company Vyrsa Technologies in a deal valued at around $75m.

As per the transaction, Nevro made a $40m payment at closing and committed up to an additional $35m, either in cash or stock, based on reaching specific milestones in development and sales.

Nevro CMO David Caraway said: “Vyrsa’s comprehensive product suite allows physicians to tailor therapy to specific patient needs. Their innovative implants provide optimal stability and enhance the opportunity for the SI joint to fuse, providing relief to patients suffering from chronic SI joint pain.”

Vyrsa specialises in providing a less invasive treatment for individuals with chronic SI joint pain.

Established in 2021, it is claimed to be the only SI joint company that produces and supports a complete portfolio of FDA-approved SI joint fusion devices.

Vyrsa’s range of devices enables physicians to use Category I CPT codes for SI joint fusion procedures at all approved service locations.

Nevro CEO Kevin Thornal said: “The acquisition of Vyrsa leverages Nevro’s ability to drive long-term shareholder value by accelerating our key strategic initiatives of commercial execution, market penetration, and profit progress.

“Vyrsa offers differentiated implants to our current call point of physicians that will help drive growth. We are ecstatic to be able to bring long-term pain relief to the 15%-30% of people suffering with chronic low back pain associated with the SI joint.”

Nevro has also finalised a six-year, $200m term loan credit facility. The funds obtained will be used to repurchase a significant portion of its 2025 convertible notes and for general corporate purposes and working capital.

In April 2023, Nevro recruited the first patient in the Painful Diabetic Neuropathy (PDN) Sensory Study to assess the restoration of neurological function in patients with intractable PDN.

The aging population is a captive market for medical devices

The rising number of older individuals globally is accompanied by increasing health concerns, presenting unique demand for the medical device industry. With rising pressure on governments, payers, and manufacturers to reduce healthcare costs, innovative medical technologies have tremendous potential to improve elder care. Advancements in medical device technology have resulted in a significant increase in the number of conditions that can be managed in a home care setting. To capitalize on this strong demand and growth, manufacturers are increasingly producing consumer-targeted equipment.

Newsletters by sectors


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.